Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.61 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29963641 | 0.84 | APOBEC3G (0.60) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL30082691 | 0.84 | AGER (0.59) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL26413518 | 0.81 | MAPT (0.65) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL82589 | 0.81 | MAPT (0.65) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL5880406 | 0.81 | MAPT (0.65) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL29283438 | 0.80 | TSHR (0.50) | AGERCA12CA9GAACA1 | |
| SCHEMBL29290107 | 0.80 | AGER (0.55) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL7022399 | 0.79 | APOBEC3G (0.67) | C5AR1CA12CA9LMNAHTR2A | |
| SCHEMBL31729683 | 0.78 | MAPT (0.57) | AGERMAPTMCOLN3C5AR1CA12 | |
| SCHEMBL6990099 | 0.78 | MAPT (0.61) | AGERMAPTMCOLN3C5AR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1240707-C | 2-Halo-6-0-substituted ketolide derivatives | ABBOTT LAB (US) | 2006-02-08 | — | — | CN | claimed |
| EP-1027362-B1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | ABBOTT LAB (US) | 2005-06-29 | — | — | EP | claimed |
| US-6727229-B2 | MACROLIDE ANTIBIOTICS PLAY A THERAPEUTICALLY IMPORTANT ROLE, PARTICULARLY WITH THE EMERGENCE OF NEW PATHOGENS | ENANTA PHARMACEUTICALS, INC. | 2004-04-27 | — | — | US | claimed |
| WO-2004016634-A1 | Novel 11,12-Substituted Lactone Ketolide Derivatives Having Antibacterial Activity | ENANTA PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | claimed |
| CN-1283199-A | 2-Halo-6-0-substituted ketolide derivatives | ABBOTT LAB (US) | 2001-02-07 | — | — | CN | claimed |
| US-6124269-A | NOVEL ERYTHROMYCIN DERIVATIVE ANTIBIOTIC EFFECTIVE AGAINST GRAM-NEGATIVE BACTERIA AND HAVING LESS POTENTIAL FOR DEVELOPING BACTERIAL DRUG RESISTANCE | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | claimed |
| EP-1027362-A1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | Abbott Laboratories (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021871-A1 | 2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-05-06 | — | — | WO | claimed |
| US-20230272272-A1 | Surface Treatment Of Quantum Dots | UNITED STATES DEPARTMENT OF ENERGY | 2023-08-31 | — | — | US | disclosed |
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| CN-101955508-B | 6-11 dicycloketone macrolide derivative | ENANTA PHARM INC | 2015-04-15 | — | — | CN | disclosed |
| EP-0227472-B1 | 10 BETA-ALKYNYLESTRENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4808578-A | ANTICARCINOGENIC AGENTS | FARMITALIA CARLO ERBA S. R. L. (IT) | 1989-02-28 | — | — | US | disclosed |
| US-4751245-A | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E. R. SQUIBB & SONS, INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0251574-A2 | Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same | E.R. Squibb & Sons, Inc. (US) | 1988-01-07 | — | — | EP | disclosed |
| EP-0227472-A1 | 10 Beta-alkynylestrene derivatives and process for their preparation | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-07-01 | — | — | EP | disclosed |
| US-4479901-A | Fluorination of carbanions with N-fluoro-N-alkylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | AGER 4395/4885MAPT 4745/4885MCOLN3 2385/4885 |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | CYP51A1, SI, VIP | AGER 3823/4885MAPT 4299/4885MCOLN3 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.